» Articles » PMID: 16830652

Persister Studies in Leprosy Patients After Multi-drug Treatment

Overview
Date 2006 Jul 13
PMID 16830652
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Cutaneous biopsies were collected from leprosy patients who attended the out-patient department of the Institute for treatment at different intervals, i.e., 12 months, 18 months, 24 months, 36 months, and more after beginning the multi-drug treatment therapy (M.D.T.). The patients belonged to the two drug regimens; (i) standard multibacillary (MB) M.D.T. after 12, 24, and 36 months; or (ii) standard M.D.T. + Minocycline 100 mg once a month (supervised) + Ofloxacin 400 mg once a month supervised for 12 months Biopsies were processed for mouse footpad inoculation and for estimating ATP levels by bioluminescence assay as per established methods. Viable bacilli were observed in 23.5% up to 1 year, 7.1% at 2 years, and in 3.84% at 3 years of M.D.T. by MFP and 29.4%, 10.7%, and 3.84% by ATP assay in the M.D.T. group at the same time period, respectively, but not in M.D.T. + Minocycline + Ofloxacin group after one year. The overall percentage of persisters was 5.55% by MFP and 7.14% by ATP assay up to 3 years of treatment.

Citing Articles

A Cross-Sectional Study to Evaluate the Alteration of Cytokine Expression and Activation of Inflammatory Pathway in Response to NOD1 and NOD2 Signal in Leprosy.

Hasanoor Reja A, De A, Chakraborty D, Ahmed S, Sarda A Indian J Dermatol. 2024; 68(6):724.

PMID: 38371539 PMC: 10868971. DOI: 10.4103/ijd.ijd_386_23.


Drug Resistance in in the Context of Zero Leprosy.

Singh I, Sengupta U Indian Dermatol Online J. 2021; 12(6):791-795.

PMID: 34934713 PMC: 8653743. DOI: 10.4103/idoj.idoj_599_21.


Genomic Reduction at TTC Repeats in the Bacterial Genome of Treated Cases of Hansen's Disease: A Possible Survival Mechanism of .

Hasanoor Reja A, De A, Patra P, Biswas S, Duttagupta U, Sil A Indian J Dermatol. 2018; 63(6):449-454.

PMID: 30504970 PMC: 6233034. DOI: 10.4103/ijd.IJD_90_18.


Alternate Anti-Leprosy Regimen for Multidrug Therapy Refractory Leprosy: A Retrospective Study from a Tertiary Care Center in North India.

Narang T, Bishnoi A, Dogra S, Nahar Saikia U, Kavita Am J Trop Med Hyg. 2018; 100(1):24-30.

PMID: 30298809 PMC: 6335923. DOI: 10.4269/ajtmh.18-0256.


Longitudinal immune profiles in type 1 leprosy reactions in Bangladesh, Brazil, Ethiopia and Nepal.

Khadge S, Banu S, Bobosha K, van der Ploeg-van Schip J, Goulart I, Thapa P BMC Infect Dis. 2015; 15:477.

PMID: 26510990 PMC: 4625471. DOI: 10.1186/s12879-015-1128-0.